Your browser doesn't support javascript.
loading
Repeatability of nasal allergen challenge results: Further validation of the allergic rhinitis clinical investigator collaborative protocols.
Soliman, Mena; Steacy, Lisa M; Thiele, Jenny; Adams, Dan E; Neighbour, Helen L; Ellis, Anne K.
Afiliação
  • Soliman M; Allergy Research Unit, Kingston General Hospital, Kingston, Ontario, Canada.
  • Steacy LM; Allergy Research Unit, Kingston General Hospital, Kingston, Ontario, Canada.
  • Thiele J; Division of Allergy and Immunology, Department of Medicine, Queen's University, Kingston, Ontario, Canada.
  • Adams DE; Allergy Research Unit, Kingston General Hospital, Kingston, Ontario, Canada.
  • Neighbour HL; Divisions of Clinical Immunology and Allergy and Respirology, Department of Medicine, Firestone Institute of Respiratory Health, The Research Institute at St. Joe's Hamilton and McMaster University, Hamilton, Ontario, Canada.
  • Ellis AK; Allergy Research Unit, Kingston General Hospital, Kingston, Ontario, Canada; Division of Allergy and Immunology, Department of Medicine, Queen's University, Kingston, Ontario, Canada. Electronic address: ellisa@queensu.ca.
Ann Allergy Asthma Immunol ; 120(6): 607-613, 2018 06.
Article em En | MEDLINE | ID: mdl-29432965
ABSTRACT

BACKGROUND:

Nasal allergen challenge (NAC) models have been used to study allergic rhinitis and new therapies. Symptoms and biological samples can be evaluated at time points after allergen exposure.

OBJECTIVE:

To verify protocol repeatability and adequate interval between allergen exposures.

METHODS:

Ten ragweed allergic participants were exposed to incrementally increasing dosages of ragweed allergen intranasally until they achieved a total nasal symptom score (TNSS) of 8 of 12 and a peak nasal inspiratory flow (PNIF) of 50% reduction or more from baseline. Three weeks later, participants were challenged with a cumulative dose equal to the sum of all the allergen doses received at screening. TNSS and PNIF were recorded at regular intervals, including a 24-hour assessment. A subsequent visit was conducted after a further 3 weeks. Nasal secretion samples were collected for cytokine and eosinophil quantification.

RESULTS:

Nine participants completed all visits. TNSS and PNIF responses followed previous patterns, with an initial peak at 30 minutes followed by a gradual decline. Most participants reported similar patterns at both NAC visits, although some did not demonstrate the same phenotype at both visits. Some experienced a secondary symptom increase 24 hours after NAC. Eosinophil and cytokine sections followed a similar pattern at both NAC visits.

CONCLUSION:

NAC is an adequate method for modeling AR in humans, demonstrating appropriate repeatability of symptoms, nasal mucosal eosinophil, and cytokines. The 24-hour time point, previously not studied in our model, may be beneficial in evaluation of long-acting medications. This three-week interval NAC model will be beneficial for studies in which before and after treatment comparisons are desired.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pólen / Alérgenos / Ambrosia Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pólen / Alérgenos / Ambrosia Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies Limite: Adult / Female / Humans / Male Idioma: En Ano de publicação: 2018 Tipo de documento: Article